phrykt

Mineralys Therapeutics, Inc. (MLYS): who owns it and who trades it

As of Nov 16, 2026, MLYS insiders reported 58 open-market sales worth $71.3M and 2 purchases worth $8.8M in the last 12 months, with 35% of the sale value made under pre-set 10b5-1 plans. The largest seller was Catalys Pacific Fund, LP (10% owner), with $43.4M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Mineralys Therapeutics

From the latest filings

Overall: about as much buying as selling. Famous investors mostly sold. Funds and insiders were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns MLYS

226 funds and institutions reported MLYS shares worth $2.8B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Catalys Pacific, LLC with 9.6%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Catalys Pacific, LLC9.6%
Ra Capital Management, L.P.9.3%
BlackRock, Inc.7.1%
Samsara Biocapital, LLC7.1%
FMR LLC (Fidelity)5.5%
State Street Corp5.0%
Deerfield Management Company, L.P.4.8%
Vanguard Capital Management LLC3.3%
Laurion Capital Management LP3.0%
T. Rowe Price Associates2.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Catalys Pacific, LLC7.90M9.59%$213MNo change
Ra Capital Management, L.P.7.69M9.34%$208MNo change
BlackRock, Inc.5.89M7.14%$159M+31%
Samsara Biocapital, LLC5.87M7.13%$158MNo change
FMR LLC (Fidelity)4.51M5.48%$122M-7%
State Street Corp4.14M5.03%$112M+41%
Deerfield Management Company, L.P.3.96M4.80%$107M–
Vanguard Capital Management LLC2.76M3.35%$74.4M+12%
Laurion Capital Management LP2.51M3.04%$67.6M+12%
T. Rowe Price Associates2.26M2.75%$61M+68%
Orbimed Advisors LLC2.11M2.56%$56.9M+3%
Capital World Investors2.00M2.42%$53.9M+402%
California State Teachers Retirement System1.81M2.20%$67.2M+2860%
Armistice Capital, LLC1.74M2.11%$46.8M+48%
Troluce Capital Advisors LLC1.73M2.10%$46.6M+164%
Nantahala Capital Management, LLC1.64M1.99%$44.3M+83%
Franklin Resources Inc1.64M1.98%$44.1M-8%
Andera Partners1.59M1.93%$42.9MNo change
Geode Capital Management, LLC1.58M1.92%$42.8M+22%
SR One Capital Management, LP1.56M1.90%$42.2MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, MLYS insiders reported $8.8M of open-market purchases and $71.3M of sales. 35% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$8.8M
2 trades, 1 people
Sales, 12 months
$71.3M
58 trades, 7 people
Sales under a 10b5-1 plan
35%
Share of sale value
Latest trade
Sep 30, 2026
Filed Oct 2, 2026

Purchases and sales by month

$11.1M$11.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 30, 2026Jon CongletonCEOSale plan75,000$25.46$1.9MForm 4
Sep 22, 2026Brian Taylor SlingsbyDirectorSale104,320$28.81$3MForm 4
Sep 21, 2026Eric WarrenChief Commercial OfficerSale plan7,438$28.12$209KForm 4
Sep 15, 2026Daphne KarydasDirectorSale plan3,000$28.58$85.7KForm 4
Aug 21, 2026Eric WarrenChief Commercial OfficerSale plan7,437$25.98$193KForm 4
Aug 10, 2026David Malcom RodmanChief Medical OfficerSale plan2,170$27.09$58.8KForm 4
Jul 21, 2026Eric WarrenChief Commercial OfficerSale plan7,438$26.87$200KForm 4
Jul 17, 2026David Malcom RodmanChief Medical OfficerSale plan416$26.53$11KForm 4
Jul 15, 2026David Malcom RodmanChief Medical OfficerSale plan6,349$26.61$169KForm 4
Jul 13, 2026Jon CongletonCEOSale plan10,700$27.24$291KForm 4
Jul 13, 2026David Malcom RodmanChief Medical OfficerSale plan14,058$27.58$388KForm 4
Jul 9, 2026David Malcom RodmanChief Medical OfficerSale plan2,171$30.30$65.8KForm 4
Jun 30, 2026Jon CongletonCEOSale plan17,000$26.82$456KForm 4
Jun 30, 2026Jon CongletonCEOSale plan58,000$25.94$1.5MForm 4
Jun 26, 2026Eric WarrenChief Commercial OfficerSale plan104,124$25.90$2.7MForm 4
Jun 17, 2026David Malcom RodmanChief Medical OfficerSale plan4,584$25.00$115KForm 4
Jun 17, 2026Daphne KarydasDirectorSale plan3,000$25.00$75KForm 4
Jun 15, 2026David Malcom RodmanChief Medical OfficerSale plan9,890$23.81$235KForm 4
Jun 12, 2026David Malcom RodmanChief Medical OfficerSale plan6,349$23.93$152KForm 4
Jun 10, 2026David Malcom RodmanChief Medical OfficerSale plan2,170$25.00$54.2KForm 4
May 18, 2026David Malcom RodmanChief Medical OfficerSale plan417$27.55$11.5KForm 4
May 13, 2026David Malcom RodmanChief Medical OfficerSale plan14,056$28.58$402KForm 4
May 12, 2026David Malcom RodmanChief Medical OfficerSale plan6,348$29.36$186KForm 4
May 11, 2026David Malcom RodmanChief Medical OfficerSale plan2,171$29.71$64.5KForm 4
Apr 17, 2026David Malcom RodmanChief Medical OfficerSale plan416$31.33$13KForm 4
Apr 15, 2026David Malcom RodmanChief Medical OfficerSale plan6,348$27.66$176KForm 4
Apr 13, 2026David Malcom RodmanChief Medical OfficerSale plan14,058$26.54$373KForm 4
Apr 13, 2026Jon CongletonCEOSale plan15,730$26.83$422KForm 4
Apr 9, 2026David Malcom RodmanChief Medical OfficerSale plan2,170$27.38$59.4KForm 4
Mar 31, 2026Jon CongletonCEOSale plan19,364$25.50$494KForm 4
Mar 31, 2026Jon CongletonCEOSale plan453$27.05$12.3KForm 4
Mar 31, 2026Jon CongletonCEOSale plan55,183$26.54$1.5MForm 4
Mar 31, 2026Daphne KarydasDirectorSale plan3,000$25.00$75KForm 4
Mar 30, 2026Rajeev M. Shah +4DirectorPurchase58,300$24.16$1.4MForm 4
Mar 27, 2026Rajeev M. Shah +4DirectorPurchase310,700$23.67$7.4MForm 4
Mar 17, 2026David Malcom RodmanChief Medical OfficerSale plan417$25.65$10.7KForm 4
Mar 13, 2026David Malcom RodmanChief Medical OfficerSale plan253$27.82$7KForm 4
Mar 13, 2026David Malcom RodmanChief Medical OfficerSale plan10,726$25.91$278KForm 4
Mar 13, 2026David Malcom RodmanChief Medical OfficerSale plan3,079$27.37$84.3KForm 4
Mar 12, 2026David Malcom RodmanChief Medical OfficerSale plan6,348$27.37$174KForm 4
Mar 9, 2026David Malcom RodmanChief Medical OfficerSale plan2,171$26.84$58.3KForm 4
Feb 17, 2026David Malcom RodmanChief Medical OfficerSale plan417$27.59$11.5KForm 4
Feb 13, 2026David Malcom RodmanChief Medical OfficerSale plan4,166$27.33$114KForm 4
Feb 13, 2026David Malcom RodmanChief Medical OfficerSale plan6,348$27.58$175KForm 4
Feb 13, 2026David Malcom RodmanChief Medical OfficerSale plan3,541$27.33$96.8KForm 4
Feb 12, 2026David Malcom RodmanChief Medical OfficerSale plan521$29.64$15.4KForm 4
Feb 12, 2026David Malcom RodmanChief Medical OfficerSale plan5,828$28.94$169KForm 4
Feb 9, 2026David Malcom RodmanChief Medical OfficerSale plan2,171$30.21$65.6KForm 4
Jan 20, 2026David Malcom RodmanChief Medical OfficerSale plan416$32.10$13.4KForm 4
Jan 14, 2026David Malcom RodmanChief Medical OfficerSale plan11,367$32.61$371KForm 4
Jan 13, 2026David Malcom RodmanChief Medical OfficerSale plan7,709$32.75$252KForm 4
Jan 12, 2026Jon CongletonCEOSale plan9,119$32.21$294KForm 4
Jan 12, 2026Jon CongletonCEOSale plan7,117$33.15$236KForm 4
Jan 12, 2026Adam Scott LevyCFOSale plan10,758$32.14$346KForm 4
Jan 12, 2026David Malcom RodmanChief Medical OfficerSale plan6,348$32.32$205KForm 4
Jan 9, 2026David Malcom RodmanChief Medical OfficerSale plan2,170$33.27$72.2KForm 4
Jan 5, 2026David Malcom RodmanChief Medical OfficerSale plan53,470$35.53$1.9MForm 4
Jan 5, 2026David Malcom RodmanChief Medical OfficerSale plan139,245$34.83$4.8MForm 4
Jan 2, 2026David Malcom RodmanChief Medical OfficerSale plan70,037$35.87$2.5MForm 4
Nov 20, 2025Catalys Pacific Fund, LP +110% ownerSale1.00M$43.35$43.4MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Catalys Pacific Fund, LP10% owner–$43.4MNov 20, 2025
David Malcom RodmanChief Medical Officer–$14MAug 10, 2026
Rajeev M. ShahDirector$8.8M–Mar 30, 2026
Jon CongletonChief Executive Officer, Director–$7.1MSep 30, 2026
Eric WarrenChief Commercial Officer–$3.3MSep 21, 2026
Brian Taylor SlingsbyDirector–$3MSep 22, 2026
Adam Scott LevyCFO and Secretary–$346KJan 12, 2026
Daphne KarydasDirector–$236KSep 15, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MLYS short interest

Moderate short interest. 8.7% of MLYS shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 15%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 7.69M MLYS shares were sold short, 8.7% of the shares outstanding, up 3.3% from the report before. At the average daily volume of 1.55M shares, buying them all back would take about 5.0 trading days (days to cover).

Shares short, % of all shares

8.68%May 15Oct 3014.2%

Days to cover

5.0May 15Oct 3016.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20267.69M8.68%+3%1.55M5.0
Oct 15, 20267.44M8.41%-5%1.40M5.3
Sep 30, 20267.81M8.83%-15%1.51M5.2
Sep 15, 20269.18M10.39%-2%1.44M6.4
Aug 31, 20269.33M10.56%-3%818,57411.4
Aug 14, 20269.65M10.91%+4%744,75512.9
Jul 31, 20269.31M11.30%-3%618,17815.1
Jul 15, 20269.55M11.59%-14%976,4989.8
Jun 30, 202611.10M13.47%+28%2.12M5.2
Jun 15, 20268.70M10.56%-8%2.48M3.5
May 29, 20269.48M11.50%+5%1.39M6.8
May 15, 20269.02M10.95%+6%1.10M8.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Mineralys Therapeutics company events

Mineralys Therapeutics filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026LeadershipDerek DiRocco, Ph.D. informed the Board of Directors (the Board) of the Company of his decision to resign from the Board, effective as of December 31, 2026. Filing
  2. Oct 29, 2026AgreementMineralys Therapeutics, Inc. (the Company) and Tanabe Pharma Corporation (Tanabe) were previously parties to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023, May 29, 2025 and June 2, 2026 (as amended, the License Agreement), pursuant to which… Filing
  3. Oct 19, 2026LeadershipThe Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven to nine directors. Filing
  4. Aug 11, 2026LeadershipThe Company’s Board of Directors (the Board) appointed James J. Ferguson III, M.D., as the Company’s new Chief Medical Officer, effective August 10, 2026, replacing David Rodman, M.D., who remains with the Company on a full-time basis as a Strategic Advisor. Filing
  5. Jun 3, 2026AnnouncementMineralys Therapeutics, Inc. entered into an underwriting agreement with BofA Securities, Inc., Goldman Sachs & Co. LLC and Evercore Group L.L.C., relating to the issuance and sale of 5,660,378 shares of the Company’s common stock, par value $0.0001 per share. Filing
  6. Jun 3, 2026AgreementMineralys Therapeutics, Inc. entered into a fourth amendment to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023 and May 29, 2025, between the Company and Tanabe Pharma Corporation for the purposes of terminating the Company’s potential future… Filing
  7. May 22, 2026VoteReported shareholder vote results. Filing
  8. May 6, 2026ResultsReleased financial results. Filing
  9. Mar 12, 2026ResultsReleased financial results. Filing
  10. Mar 9, 2026AnnouncementThe FDA notified the Company that its NDA for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs had been accepted. Filing
  11. Jan 6, 2026AnnouncementThe Company issued a press release disclosing that it (i) filed a new drug application for lorundrostat to the U.S. Food and Drug Administration in late 2025 and (ii) remains on track to report topline results from its Phase 2 Explore-OSA trial, which is evaluating the safety and efficacy of… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Mineralys Therapeutics financials

Famous investors that hold MLYS

5 of the 50 well-known investors we track reported holding MLYS in their latest 13F filing. The largest position is Steve Cohen's, worth $31.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20261.27M$31.9M0.1%New
Israel Englander · Millennium ManagementQ3 2026708,360$17.8M0.0%-42%
Jim Simons · Renaissance TechnologiesQ3 2026417,131$10.5M0.0%+10%
Ken Griffin · Citadel AdvisorsQ3 2026263,276$6.6M0.0%-44%
Paul Tudor Jones · Tudor Investment CorpQ3 202656,743$1.4M0.0%-92%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Mineralys Therapeutics, Inc. (MLYS) stock

Who owns the most MLYS stock?

The largest reported owner of Mineralys Therapeutics, Inc. (MLYS) is Catalys Pacific, LLC, with 9.6% of the company. In total, 226 funds and institutions reported holding MLYS at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are MLYS insiders buying or selling?

In the last 12 months, MLYS insiders reported 2 open-market purchases worth $8.8M and 58 sales worth $71.3M. The latest trade was on Sep 30, 2026. See every trade.

What is the short interest in MLYS?

As of Oct 30, 2026, 7.69M MLYS shares were sold short, 8.7% of the shares outstanding, up 3.3% from the report before. At the average daily volume of 1.55M shares, buying them all back would take about 5.0 trading days (days to cover). See the history.

Which famous investors hold MLYS?

5 of the 50 well-known investors we track reported MLYS in their latest 13F filing, including Steve Cohen, Israel Englander, Jim Simons. The largest position is worth $31.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.